We would like to thank IS for his funding support towards the publication and the Institute for Neurocience, UTGV School of Medicine
[21] [3] Hepatic impairment is also relevant: vildagliptin, for example, should be avoided in patients with hepatic impairment, and liver function tests (LFTs) should be monitored during treatment as specified in its SmPC
GHRP-6 is effective at increasing growth hormone levels, which can lead to various benefits such as enhanced muscle growth, improved fat loss, and better recovery from injuries
For researchers considering long-term use, regular IGF-1 monitoring becomes essential
The growing demand and approvals for GLP-1's is essentially a sign that access and use will become inevitable and I'd speak to that separately
Private insurers might have more flexibility, but only if the notes are clear and the medical necessity is solid